Mark Genovese
Academic Appointments
- Professor - Med Center Line, Medicine - Immunology & Rheumatology
Key Documents
Contact Information
-
Clinical Offices
Immunology & Rheumatology Clinic 300 Pasteur Dr A100 MC 5309 Stanford, CA 94305 Tel Work (650) 723-6961 Fax (650) 725-8418
- Academic Offices
Personal Information Email Tel (650) 498-4528Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Rheumatology
- Immunology/Rheumatology
Professional Education
| Fellowship: | Stanford University Medical Center CA (1998) |
| Residency: | Stanford University Medical Center CA (1996) |
| Residency: | Stanford University Medical Center CA (1995) |
| Internship: | Stanford University Medical Center CA (1993) |
| Medical Education: | Johns Hopkins University MD (1992) |
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Clinical trials and interventions in the rheumatic diseases including Rheumatoid Arthritis,Systemic Lupus Erythematosus, Systemic Sclerosis, Osteoarthritis.
Publications
- Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2013; (4): 369-78
- Effects of sclerostin antibody on healing of a non-critical size femoral bone defect. J Orthop Res. 2013; (1): 155-63
- Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol. 2013; (5): 579-89
- Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013; (6): 863-9
- Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. J Rheumatol. 2013; (6): 768-780
- Novel small molecule therapeutics in rheumatoid arthritis. Rheumatology (Oxford). 2013
Help